Compare Merck & Co., Inc. (MRK) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while Global X NASDAQ 100 Covered Call ETF trades at $18.35. The key difference: Merck & Co., Inc. pays a 2.29% dividend while Global X NASDAQ 100 Covered Call ETF pays none. Which is the better fit depends on your goals.
| MRK | QYLD | |
|---|---|---|
Market Cap | $366.28B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $156.43 | $18.52 |
52-Week Low | $77.60 | $16.70 |
Enterprise Value | $413.04B | — |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
QYLD trades at $18.37, showing minimal daily movement with a 0.05% gain. The ETF maintains a bullish technical outlook with strong moving average signals, though oscillators indicate neutral momentum. Recent dividend payments of $0.18-0.19 per share continue its income-focused strategy, but news coverage highlights concerns about long-term principal erosion compared to Nasdaq-100 index performance.
The covered-call strategy provides consistent monthly income but sacrifices upside potential during market rallies. While the 12% yield attracts income investors, long-term performance has significantly lagged the underlying index. Current technical strength suggests near-term stability, but structural limitations pose challenges for capital appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
